Skip to main content
Rein Therapeutics, Inc. logo

Rein Therapeutics, Inc. — Investor Relations & Filings

Ticker · RNTX ISIN · US00887A2042 US Manufacturing
Filings indexed 408 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country US United States of America
Listing US RNTX

About Rein Therapeutics, Inc.

https://www.reintx.com/

Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel, first-in-class therapies for significant unmet medical needs in orphan pulmonary diseases and fibrosis. The company's primary focus is on advancing its pipeline to improve lung function and enhance the quality of life for patients. Its lead product candidate, LTI-03, is a treatment for Idiopathic Pulmonary Fibrosis (IPF) and is undergoing a Phase 2 clinical trial.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report
2026-05-15 English
424B5 - Rein Therapeutics, Inc. (0001420565) (Filer)
Prospectus
2026-05-04 English
S-1 - Rein Therapeutics, Inc. (0001420565) (Filer)
Registration Form
2026-04-28 English
10-K/A - Rein Therapeutics, Inc. (0001420565) (Filer)
Annual Report
2026-04-27 English
10-K - Rein Therapeutics, Inc. (0001420565) (Filer)
Annual Report FY 2025
2026-03-26 English
8-K - REIN THERAPEUTICS, INC. (0001420565) (Filer)
Regulatory Filings
2026-03-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.